40.38% after-hours surge: 2211.HK Universal Health (HKSE) volume 6.80M 10 Mar 2026

The 2211.HK stock raced higher after hours on 10 Mar 2026, closing at HKD 0.73, up 40.38% on 6,801,301 shares traded. This heavy volume move makes Universal Health International Group Holding Limited (2211.HK) a clear high-volume mover on the HKSE in Hong Kong. The jump followed an intraday low of HKD 0.50 and a previous close of HKD 0.52. Traders will watch whether volume confirms a trend or a short-covering spike.

2211.HK stock: price action and volume drivers

2211.HK stock rose to HKD 0.73 in after-hours trade on 10 Mar 2026, after opening at HKD 0.50 and touching a day low of HKD 0.50. The 6,801,301 share volume was nearly double the average daily volume of 3,566,449, signalling elevated trader interest. The one-day price change registered +40.38%, while the 50-day average price sits at HKD 1.54 and the 200-day average at HKD 1.51.

High volume with a close at the session high suggests strong demand. Short-term momentum indicators show the stock is oversold-to-neutral; confirmation requires follow-through in the next session with sustained volume above the 3.57M average.

Valuation and fundamentals for Universal Health (2211.HK stock)

Universal Health reports EPS of -0.37 and a trailing PE of -1.38, reflecting recent negative earnings. Price-to-book is 0.11 and price-to-sales is 0.06, indicating the market values the shares well below book. Market capitalization stands at HKD 45,282,944.00, with 88,790,087 shares outstanding.

Key ratios show a current ratio of 1.31, debt-to-equity of 0.08, and free cash flow yield of 21.74%. These metrics point to low leverage but thin profitability. The company operates in Healthcare, Medical – Pharmaceuticals, serving northeast China with wholesale and retail drug distribution.

Meyka AI rates 2211.HK with a score out of 100 and technical read

Meyka AI rates 2211.HK with a score out of 100: 64.29 / 100 (Grade B) — SUGGESTION: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus. Grades are informational and not investment advice.

Technicals: RSI 33.39 (near oversold), MACD -0.34 with histogram 0.03, and ADX 34.01 indicating a strong trend. Bollinger Bands are 0.48–0.84 with a middle at 0.66. Momentum oscillators show oversold readings; risk remains high until MACD and RSI confirm recovery.

Catalysts, sector context and risks for 2211.HK stock

Catalysts include regional demand for pharmaceutical distribution, inventory cycles, and periodic earnings updates. The company last announced earnings on 25 Feb 2025. Healthcare sector momentum in Hong Kong has lagged the broader market, but drug distributors can gain from tighter supply chains.

Key risks are weak profitability (net margin -3.66%), volatile share liquidity, and a year high at HKD 5.36 versus a year low at HKD 0.49. Regulatory or margin pressure in China’s pharma sector could quickly affect valuation.

Price targets, Meyka AI’s forecast and implied upside

Meyka AI’s forecast model projects a 12-month price of HKD 3.20. Compared with the current price of HKD 0.73, that implies an upside of +339.00%. Short-term model forecasts list monthly HKD 0.58 and quarterly HKD 2.16.

Realistic analyst-style targets for risk management: a near-term recovery target of HKD 1.50 (guided by 50/200-day averages), and a longer-term target aligned with Meyka’s model at HKD 3.20. Forecasts are model-based projections and not guarantees.

Trading strategy and outlook for active traders

For high-volume movers, short-term traders should watch intraday volume and the next session’s relative volume vs 3,566,449 average. A breakout above HKD 0.80 on rising volume would support momentum trades. Risk-managed stop-losses near HKD 0.50 limit downside to the recent low.

Longer-term investors should weigh book value per share HKD 3.96 and cash flow metrics against negative EPS. Consider position sizing that reflects high volatility and the stock’s thin market cap.

Final Thoughts

2211.HK stock showed a pronounced after-hours move on 10 Mar 2026, rising to HKD 0.73 on heavy volume of 6,801,301 shares. The move makes Universal Health a high-volume mover on the HKSE in Hong Kong. Valuation reads cheap by price-to-book (0.11) and price-to-sales (0.06), but negative EPS (-0.37) and margins signal profit weakness. Meyka AI rates 2211.HK with a score of 64.29/100 (Grade B — HOLD), balancing low leverage and solid book value against operating losses. Meyka AI’s forecast model projects HKD 3.20 in 12 months, implying +339.00% from today’s price; forecasts are model-based projections and not guarantees. Traders seeking short-term gains should demand follow-through volume above the average 3,566,449 share level and confirm technicals. Longer-term investors must balance upside potential with execution risk, thin liquidity and sector sensitivity. For more context, see the latest market note on Investing.com and company filings on the Universal Health site at uhighl.com. Meyka AI provides this analysis as an AI-powered market analysis platform; these observations are informational and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.